These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 22968544)
1. Efficacy and safety of beta-interferon in Thai patients with demyelinating diseases. Jarernsook B; Siritho S; Prayoonwiwat N Mult Scler; 2013 Apr; 19(5):585-92. PubMed ID: 22968544 [TBL] [Abstract][Full Text] [Related]
2. Interferon-beta(1b) treatment in neuromyelitis optica. Tanaka M; Tanaka K; Komori M Eur Neurol; 2009; 62(3):167-70. PubMed ID: 19590215 [TBL] [Abstract][Full Text] [Related]
3. Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders. Fragomeni MO; Bichuetti DB; Oliveira EML Mult Scler Relat Disord; 2018 Oct; 25():138-142. PubMed ID: 30075406 [TBL] [Abstract][Full Text] [Related]
4. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Uzawa A; Mori M; Hayakawa S; Masuda S; Kuwabara S Eur J Neurol; 2010 May; 17(5):672-6. PubMed ID: 20039942 [TBL] [Abstract][Full Text] [Related]
5. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Kim SH; Kim W; Li XF; Jung IJ; Kim HJ Mult Scler; 2012 Oct; 18(10):1480-3. PubMed ID: 22354738 [TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. Nikfar S; Rahimi R; Abdollahi M Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of interferon β-1b in Japanese patients with optic-spinal multiple sclerosis. Shimizu Y; Fujihara K; Kubo S; Takahashi T; Misu T; Nakashima I; Yokoyama K; Itoyama Y; Uchiyama S Tohoku J Exp Med; 2011 Mar; 223(3):211-4. PubMed ID: 21403431 [TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Papeix C; Vidal JS; de Seze J; Pierrot-Deseilligny C; Tourbah A; Stankoff B; Lebrun C; Moreau T; Vermersch P; Fontaine B; Lyon-Caen O; Gout O Mult Scler; 2007 Mar; 13(2):256-9. PubMed ID: 17439893 [TBL] [Abstract][Full Text] [Related]
9. Poor responses to interferon-beta treatment in patients with neuromyelitis optica and multiple sclerosis with long spinal cord lesions. Wang KC; Lin KH; Lee TC; Lee CL; Chen SY; Chen SJ; Chin LT; Tsai CP PLoS One; 2014; 9(6):e98192. PubMed ID: 24887452 [TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders. Lim YM; Kim H; Lee EJ; Kim HW; Kim HJ; Kim KK Mult Scler Relat Disord; 2020 Jul; 42():102109. PubMed ID: 32387973 [TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. Viswanathan S; Wong AH; Quek AM; Yuki N J Neuroimmunol; 2015 May; 282():92-6. PubMed ID: 25903734 [TBL] [Abstract][Full Text] [Related]
12. Interferon-β1b increases Th2 response in neuromyelitis optica. Nakajima H; Hosokawa T; Doi Y; Ikemoto T; Ishida S; Kimura F; Hanafusa T Int J Mol Sci; 2012 Sep; 13(10):12213-23. PubMed ID: 23202893 [TBL] [Abstract][Full Text] [Related]
13. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study. Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083 [TBL] [Abstract][Full Text] [Related]